COVID-19 and multiple sclerosis: challenges and lessons for patient care DOI Creative Commons
Luca Prosperini, Georgina Arrambide, Elisabeth Gulowsen Celius

et al.

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 44, P. 100979 - 100979

Published: Aug. 23, 2024

During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to interaction between SARS-CoV-2, underlying neurological disease use of disease-modifying treatments (DMTs). Key concerns arose, primarily possibility that SARS-CoV-2 infection could trigger initial demyelinating event or exacerbate activity. Another major concern was safety efficacy vaccines, especially for patients undergoing specific weaken antibody responses. In post-infection phase, identifying long COVID in MS has been complicated due large overlap sequelae symptoms. addition, disruptions health rehabilitation services made it difficult access care. This Series article explores current evidence on identifies posed by pandemic care MS, discusses significant adoption digital solutions, including telemedicine new technology-based approaches. Based lessons learned, recommendations future directions are offered managing rethinking systems improving outcomes post-COVID-19 era.

Language: Английский

COVID-19 and multiple sclerosis: challenges and lessons for patient care DOI Creative Commons
Luca Prosperini, Georgina Arrambide, Elisabeth Gulowsen Celius

et al.

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 44, P. 100979 - 100979

Published: Aug. 23, 2024

During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to interaction between SARS-CoV-2, underlying neurological disease use of disease-modifying treatments (DMTs). Key concerns arose, primarily possibility that SARS-CoV-2 infection could trigger initial demyelinating event or exacerbate activity. Another major concern was safety efficacy vaccines, especially for patients undergoing specific weaken antibody responses. In post-infection phase, identifying long COVID in MS has been complicated due large overlap sequelae symptoms. addition, disruptions health rehabilitation services made it difficult access care. This Series article explores current evidence on identifies posed by pandemic care MS, discusses significant adoption digital solutions, including telemedicine new technology-based approaches. Based lessons learned, recommendations future directions are offered managing rethinking systems improving outcomes post-COVID-19 era.

Language: Английский

Citations

3